CK1-IN-1

• UNSPSC Description:

  CK1-IN-1 is a casein kinase 1 (CK1) inhibitor extracted from patent WO2015119579A1, compound 1c, has IC50s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively[1].

• Target Antigen:

  Casein Kinase

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Stem Cell/Wnt

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ck1-in-1.html

• Purity:

  99.35

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL

• Smiles:

  FC1=CC=C(C2=C(C3=CC=NC=C3)NC(C4=CC=C5C=CC=CC5=C4F)=N2)C=C1

• Molecular Weight:

  383.39

• References & Citations:

  [1]Filip LACO,et al. 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis. WO2015119579A1.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1784751-20-7